<DOC>
	<DOCNO>NCT00371956</DOCNO>
	<brief_summary>This study double-blind placebo-controlled trial evaluate efficacy raloxifene prevention bone mineral density loss patient receive long term corticosteroid .</brief_summary>
	<brief_title>Raloxifene Prevention Bone Loss Postmenopausal Patients Receiving Chronic Corticosteroid Therapy</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>1 . Postmenopausal patient various chronic rheumatic disease receive chronic steroid therapy . 2 . Stable disease least 6 month prior study stable dose steroid ( prednisone &lt; = 10 mg/day equivalent ) . 3 . Baseline bone mineral density ( BMD ) lumbar spine T score &lt; 1.0 . 1 . Patients history thromboembolism . 2 . Patients positive antiphospholipid antibody . 3 . History allergic reaction intolerance raloxifene SERMs . 4 . Patients receive bisphosphonates , parathyroid hormone , SERMs , anticonvulsant anticytokine therapy within 6 month prior study entry . 5 . Patients know bone disorder osteomalacia , renal osteodystrophy , hyperparathyroidism . 6 . Patients abnormal uterine bleed unknown etiology . 7 . Patients serum creatinine level &gt; = 200 umol/L .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>raloxifene</keyword>
	<keyword>estrogen</keyword>
	<keyword>receptor</keyword>
	<keyword>modulation</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>steroid</keyword>
	<keyword>Steroids</keyword>
</DOC>